Skip to content
Bomb Report – Lifestyle
Author:
HOTH THERAPEUTICS, INC.
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
March 31, 2026
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
March 26, 2026
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
March 24, 2026
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
March 10, 2026
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
March 6, 2026
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
March 5, 2026
←
Previous Page
1
2